SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation.... Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity.
- Mechanism
- Curator reviewed
Induces activity of regulatory t-cells that surpress Th2 activity. CD11c+ cells act as the primary target for M. vaccae.
- Primary indication
- Investigated for use/treatment in asthma, atopic dermatitis, and pediatric atopic dermatitis indications.Curator reviewed
- Code names
- SRP 299
What you can answer from here — as of April 02, 2025
Which companies are running trials of SRP 299, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account